$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq

$seelq Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000101749118000103 Filed on October 31, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	-$3.510M	$1.930M	$2.410M
YoY Change	-245.64%	9.66%	26.84%
% of Gross Profit
Research & Development		$769.0K	$240.0K
YoY Change		-60.77%	-60.66%
% of Gross Profit
Depreciation & Amortization			$20.00K
YoY Change			-118.18%
% of Gross Profit
Operating Expenses	-$3.510M	$2.703M	$2.650M
YoY Change	-232.45%	-27.26%	5.58%
Operating Profit		-$2.703M
YoY Change		-27.26%
Interest Expense	-$510.0K	$0.00	-$50.00K
YoY Change	920.0%	-100.0%	-102.27%
% of Operating Profit
Other Income/Expense, Net	$890.0K	-$135.0K	$100.0K
YoY Change	790.0%	-53.92%
Pretax Income	$3.890M	-$2.840M	-$2.600M
YoY Change	-249.62%	-29.18%	712.5%
Income Tax
% Of Pretax Income
Net Earnings	$3.910M	-$2.838M	-$2.450M
YoY Change	-259.59%	-25.94%	716.67%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$382.6K	-$3.595M	-$4.804M
COMMON SHARES
Basic Shares Outstanding	28.17M shares	23.44M shares	15.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.00K	$5.280M	$6.330M
YoY Change	-99.37%	-37.59%	202.87%
Cash & Equivalents		$5.283M	$6.331M
Short-Term Investments
Other Short-Term Assets	$150.0K	$200.0K	$260.0K
YoY Change	-42.31%	-13.04%	-83.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$190.0K	$5.481M	$6.592M
YoY Change	-97.12%	-36.91%	81.4%
LONG-TERM ASSETS
Property, Plant & Equipment		$46.00K	$79.00K
YoY Change		-54.0%	-51.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$37.00K	$35.00K
YoY Change		5.71%	-41.67%
Total Long-Term Assets	$0.00	$83.00K	$114.0K
YoY Change	-100.0%	-38.52%	-89.31%
TOTAL ASSETS
Total Short-Term Assets	$190.0K	$5.481M	$6.592M
Total Long-Term Assets	$0.00	$83.00K	$114.0K
Total Assets	$190.0K	$5.564M	$6.706M
YoY Change	-97.17%	-36.94%	42.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.220M	$320.0K	$60.00K
YoY Change	3600.0%	23.08%	-92.11%
Accrued Expenses	$240.0K	$766.0K	$650.0K
YoY Change	-63.08%	-2.17%	-51.24%
Deferred Revenue		$0.00	$12.00K
YoY Change
Short-Term Debt	$2.440M	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$2.440M
YoY Change
Total Short-Term Liabilities	$4.900M	$1.425M	$1.583M
YoY Change	209.54%	-21.44%	-85.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$26.00K	$58.00K
YoY Change	-100.0%	-51.85%	-23.68%
Total Long-Term Liabilities	$0.00	$26.00K	$58.00K
YoY Change	-100.0%	-51.85%	-23.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.900M	$1.425M	$1.583M
Total Long-Term Liabilities	$0.00	$26.00K	$58.00K
Total Liabilities	$4.900M	$1.451M	$2.335M
YoY Change	109.85%	-42.05%	-80.89%
SHAREHOLDERS EQUITY
Retained Earnings		-$323.4M	-$316.0M
YoY Change		3.14%	-0.1%
Common Stock		$327.5M	$320.4M
YoY Change		2.38%	3.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.710M	$4.113M	$4.371M
YoY Change
Total Liabilities & Shareholders Equity	$190.0K	$5.564M	$6.706M
YoY Change	-97.17%	-36.94%	42.68%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	$3.910M	-$2.838M	-$2.450M
YoY Change	-259.59%	-25.94%	716.67%
Depreciation, Depletion And Amortization			$20.00K
YoY Change			-118.18%
Cash From Operating Activities	-$400.0K	-$540.0K	-$2.480M
YoY Change	-83.87%	-82.12%	-8.49%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$210.0K
YoY Change
Cash From Investing Activities			$210.0K
YoY Change			2000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.0K	700.0K	130.0K
YoY Change	-23.08%	-79.53%	-115.66%
NET CHANGE
Cash From Operating Activities	-400.0K	-540.0K	-2.480M
Cash From Investing Activities			210.0K
Cash From Financing Activities	100.0K	700.0K	130.0K
Net Change In Cash	-300.0K	160.0K	-2.140M
YoY Change	-85.98%	-75.38%	-39.38%
FREE CASH FLOW
Cash From Operating Activities	-$400.0K	-$540.0K	-$2.480M
Capital Expenditures			$0.00
Free Cash Flow			-$2.480M
YoY Change			-8.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	61000	USD
CY2018Q3	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	2000	USD
CY2018Q2	apri	Research And Development Number Of Phase3 Clinical Efficacy Trials Required ResearchAndDevelopmentNumberOfPhase3ClinicalEfficacyTrialsRequired	2	clinical_trial
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0
CY2017Q1	apri	Aggregate Liability Limitation Indemnification Claims AggregateLiabilityLimitationIndemnificationClaims	2000000	USD
CY2018Q3	apri	Class Of Warrant Or Right Canceled ClassOfWarrantOrRightCanceled	2677160	shares
CY2018Q3	apri	Contingent Value Right Receipt Of Cash Payments Exceeding Threshold Percentage ContingentValueRightReceiptOfCashPaymentsExceedingThresholdPercentage	0.9
CY2018Q3	apri	Contingent Value Right Sales Or Out Licensing Threshold ContingentValueRightSalesOrOutLicensingThreshold	500000	USD
CY2018Q3	apri	Contingent Value Right Term Of Cash Payout Period ContingentValueRightTermOfCashPayoutPeriod	P10Y
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	500000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Carrying Value Of Assets DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodCarryingValueOfAssets	1578000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferred	1186000	USD
	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred After Closing Date DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferredAfterClosingDate	1100000	USD
CY2018Q3	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
CY2017Q1	apri	Expected Payments For Transition Services Number Of Quarterly Payments ExpectedPaymentsForTransitionServicesNumberOfQuarterlyPayments	2	payment
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	-422000	USD
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	0	USD
	apri	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	apri	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12000	USD
	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	4792000	USD
CY2018Q3	apri	Merger Agreement Termination Fee MergerAgreementTerminationFee	500000	USD
	apri	Noncash Financing Activities Issuance Of Placement Agent Warrants NoncashFinancingActivitiesIssuanceOfPlacementAgentWarrants	287000	USD
	apri	Noncash Financing Activities Issuance Of Placement Agent Warrants NoncashFinancingActivitiesIssuanceOfPlacementAgentWarrants	159000	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	798000	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	472000	USD
CY2016Q3	apri	Proceeds From Issuance Of Sale Of Equity Net Of Transaction Costs ProceedsFromIssuanceOfSaleOfEquityNetOfTransactionCosts	9600000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	709000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	700000	USD
CY2018Q3	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2017Q1	apri	Purchase Agreement Maximum Potential Proceeds From Divestiture PurchaseAgreementMaximumPotentialProceedsFromDivestiture	12700000	USD
CY2018Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	6738000	shares
CY2018Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	1.01
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	1.48
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.41
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6376000	USD
CY2017Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	3.91
CY2018Q3	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.69
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	3.99
CY2018Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	95200000	USD
CY2018Q3	apri	Surviving Company Expected Ownership Percentage SurvivingCompanyExpectedOwnershipPercentage	0.15
	apri	Warrant Liability Reclassified To Stockholders Equity WarrantLiabilityReclassifiedToStockholdersEquity	472000	USD
CY2018Q3	apri	Working Capital WorkingCapital	4100000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28167329	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	58000	USD
CY2018Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	322000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	56000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	0	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	863000	USD
CY2018Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	316000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	650000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	766000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	575000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	672000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	320343000	USD
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	1.11
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	327458000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	985000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	689000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	293000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	332000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	903000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	429000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	985000	USD
CY2017Q4	us-gaap	Assets Assets	6706000	USD
CY2018Q3	us-gaap	Assets Assets	5564000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	6592000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	5481000	USD
CY2017Q4	us-gaap	Cash Cash	6331000	USD
CY2018Q3	us-gaap	Cash Cash	5283000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2087000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8463000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5283000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1048000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	80000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-3000	USD
CY2018Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	13095000	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15217231	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28138565	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15217231	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28138565	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	15000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	131000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	52000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33000	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	694000	USD
CY2018Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2017	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	12317000	USD
CY2017Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.01
CY2018Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
CY2018Q3	us-gaap	Disposal Group Including Discontinued Operation Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent	20000	USD
CY2017Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	12709000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.26
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	100000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	296000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	588000	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	222000	USD
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-222000	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-422000	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	39000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4799000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-63000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1756000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1934000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6144000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4009000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9150000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2838000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7362000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.30
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.85
CY2018Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.12
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.35
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	177000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	11917000	USD
CY2018Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-24000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-425000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	264000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-583000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	64000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	54000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-547000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-25000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-22000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-32000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-89000	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	92000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	2335000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	1451000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6706000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5564000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1583000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1425000	USD
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2018Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	21000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	12080000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-3000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2369000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5430000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8073000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10600000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6475000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-3832000	USD
	us-gaap	Net Income Loss NetIncomeLoss	2767000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-2838000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7386000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-293000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1125000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-135000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-70000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	3716000	USD
	us-gaap	Operating Expenses OperatingExpenses	8025000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	2703000	USD
	us-gaap	Operating Expenses OperatingExpenses	7292000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3716000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8025000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2703000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7292000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	92000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2016Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1235000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	637000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	261000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	198000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10733000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4792000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7800000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1275000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46000	USD
CY2017Q3	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
CY2018Q1	us-gaap	Recapitalization Costs RecapitalizationCosts	100000	USD
CY2018Q2	us-gaap	Recapitalization Costs RecapitalizationCosts	17000	USD
CY2018Q3	us-gaap	Recapitalization Costs RecapitalizationCosts	135000	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	293000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7129000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1960000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3226000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	769000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1148000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315987000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-323373000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	903000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	985000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0229
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0227
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1041000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3210000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	10262000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7084000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	13095000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	33000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	700000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	695000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.66
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	369000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1031000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.37
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.56
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.11
CY2018Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Modification Of Terms Incremental Compensation Cost ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost	200000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	1275000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4371000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	4113000	USD
CY2017Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	800000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13208000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10781000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23774000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21038000	shares

Files In Submission

Name	View Source	Status
0001017491-18-000103-index-headers.html	Edgar Link	pending
0001017491-18-000103-index.html	Edgar Link	pending
0001017491-18-000103.txt	Edgar Link	pending
0001017491-18-000103-xbrl.zip	Edgar Link	pending
apri-20180930.xml	Edgar Link	completed
apri-20180930.xsd	Edgar Link	pending
apri-20180930_cal.xml	Edgar Link	unprocessable
apri-20180930_def.xml	Edgar Link	unprocessable
apri-20180930_lab.xml	Edgar Link	unprocessable
apri-20180930_pre.xml	Edgar Link	unprocessable
apri9301810q.htm	Edgar Link	pending
apri93018ex311.htm	Edgar Link	pending
apri93018ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq

2018 Q4 Form 10-Q Financial Statement

#000101749118000103 Filed on October 31, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEELQ SEELOS THERAPEUTICS, INC. Stock $seelq

2018 Q4 Form 10-Q Financial Statement

#000101749118000103 Filed on October 31, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq